O	0	3	Use
O	4	6	of
B-intervention	7	18	anastrozole
O	19	22	for
O	23	29	breast
O	30	36	cancer
O	37	47	prevention
O	48	49	(
O	49	53	IBIS
O	53	54	-
O	54	56	II
O	56	57	)
O	57	58	:
O	59	63	long
O	63	64	-
O	64	68	term
O	69	76	results
O	77	79	of
O	80	81	a
O	82	92	randomised
O	93	103	controlled
O	104	109	trial
O	109	110	.

O	111	114	Two
O	115	120	large
O	121	129	clinical
O	130	136	trials
O	137	141	have
O	142	147	shown
O	148	149	a
O	150	157	reduced
O	158	162	rate
O	163	165	of
O	166	172	breast
O	173	179	cancer
O	180	191	development
O	192	194	in
O	195	199	high
O	199	200	-
O	200	204	risk
O	205	210	women
O	211	213	in
O	214	217	the
O	218	225	initial
O	226	227	5
O	228	233	years
O	234	236	of
O	237	243	follow
O	243	244	-
O	244	246	up
O	247	252	after
O	253	256	use
O	257	259	of
O	260	269	aromatase
O	270	280	inhibitors
O	281	282	(
O	282	285	MAP
O	285	286	.
O	286	287	3
O	288	291	and
O	292	305	International
O	306	312	Breast
O	313	319	Cancer
O	320	332	Intervention
O	333	338	Study
O	339	341	II
O	342	343	[
O	343	347	IBIS
O	347	348	-
O	348	350	II
O	350	351	]
O	351	352	)
O	352	353	.

O	354	358	Here
O	358	359	,
O	360	362	we
O	363	369	report
O	370	377	blinded
O	378	382	long
O	382	383	-
O	383	387	term
O	388	394	follow
O	394	395	-
O	395	397	up
O	398	405	results
O	406	409	for
O	410	413	the
O	414	418	IBIS
O	418	419	-
O	419	421	II
O	422	427	trial
O	427	428	,
O	429	434	which
O	435	443	compared
O	444	455	anastrozole
O	456	460	with
B-control	461	468	placebo
O	468	469	,
O	470	474	with
O	475	478	the
O	479	488	objective
O	489	491	of
O	492	503	determining
O	504	507	the
O	508	516	efficacy
O	517	519	of
O	520	531	anastrozole
O	532	535	for
O	536	546	preventing
O	547	553	breast
O	554	560	cancer
O	561	562	(
O	562	566	both
O	567	575	invasive
O	576	579	and
O	580	586	ductal
O	587	596	carcinoma
O	597	599	in
O	600	604	situ
O	604	605	)
O	606	608	in
O	609	612	the
O	613	617	post
O	617	618	-
O	618	627	treatment
O	628	634	period
O	634	635	.

O	636	640	IBIS
O	640	641	-
O	641	643	II
O	644	646	is
O	647	649	an
O	650	663	international
O	663	664	,
O	665	675	randomised
O	675	676	,
O	677	683	double
O	683	684	-
O	684	689	blind
O	689	690	,
O	691	698	placebo
O	698	699	-
O	699	709	controlled
O	710	715	trial
O	715	716	.

B-eligibility	717	731	Postmenopausal
I-eligibility	732	737	women
I-eligibility	738	740	at
I-eligibility	741	750	increased
I-eligibility	751	755	risk
I-eligibility	756	758	of
I-eligibility	759	769	developing
I-eligibility	770	776	breast
I-eligibility	777	783	cancer
O	784	788	were
O	789	798	recruited
O	799	802	and
O	803	807	were
O	808	816	randomly
O	817	825	assigned
O	826	827	(
O	827	828	1
O	828	829	:
O	829	830	1
O	830	831	)
O	832	834	to
O	835	841	either
O	842	853	anastrozole
O	854	855	(
O	855	856	1
O	857	859	mg
O	860	863	per
O	864	867	day
O	867	868	,
O	869	873	oral
O	873	874	)
O	875	877	or
O	878	886	matching
O	887	894	placebo
O	895	900	daily
O	901	904	for
O	905	906	5
O	907	912	years
O	912	913	.

O	914	919	After
O	920	929	treatment
O	930	940	completion
O	940	941	,
O	942	947	women
O	948	952	were
O	953	961	followed
O	962	964	on
O	965	966	a
O	967	973	yearly
O	974	979	basis
O	980	982	to
O	983	990	collect
O	991	995	data
O	996	998	on
O	999	1005	breast
O	1006	1012	cancer
O	1013	1022	incidence
O	1022	1023	,
O	1024	1029	death
O	1029	1030	,
O	1031	1036	other
O	1037	1044	cancers
O	1044	1045	,
O	1046	1049	and
O	1050	1055	major
O	1056	1063	adverse
O	1064	1070	events
O	1071	1072	(
O	1072	1086	cardiovascular
O	1087	1093	events
O	1094	1097	and
O	1098	1107	fractures
O	1107	1108	)
O	1108	1109	.

O	1110	1113	The
O	1114	1121	primary
O	1122	1129	outcome
O	1130	1133	was
B-outcome-Measure	1134	1137	all
I-outcome-Measure	1138	1144	breast
I-outcome-Measure	1145	1151	cancer
O	1151	1152	.

B-total-participants	1153	1157	3864
O	1158	1163	women
O	1164	1168	were
O	1169	1178	recruited
O	1179	1186	between
O	1187	1190	Feb
O	1191	1192	2
O	1192	1193	,
O	1194	1198	2003
O	1198	1199	,
O	1200	1203	and
O	1204	1207	Jan
O	1208	1210	31
O	1210	1211	,
O	1212	1216	2012
O	1216	1217	.

B-intervention-participants	1218	1222	1920
O	1223	1228	women
O	1229	1233	were
O	1234	1242	randomly
O	1243	1251	assigned
O	1252	1254	to
O	1255	1256	5
O	1257	1262	years
O	1263	1274	anastrozole
O	1275	1278	and
B-control-participants	1279	1283	1944
O	1284	1286	to
O	1287	1294	placebo
O	1294	1295	.

O	1296	1301	After
O	1302	1303	a
O	1304	1310	median
O	1311	1317	follow
O	1317	1318	-
O	1318	1320	up
O	1321	1323	of
O	1324	1327	131
O	1328	1334	months
O	1335	1336	(
O	1336	1339	IQR
O	1340	1343	105
O	1343	1344	-
O	1344	1347	156
O	1347	1348	)
O	1348	1349	,
O	1350	1351	a
O	1352	1354	49
O	1354	1355	%
O	1356	1365	reduction
O	1366	1368	in
B-outcome	1369	1375	breast
I-outcome	1376	1382	cancer
O	1383	1386	was
O	1387	1395	observed
O	1396	1399	for
O	1400	1411	anastrozole
O	1412	1413	(
B-iv-bin-abs	1413	1415	85
O	1416	1418	vs
B-cv-bin-abs	1419	1422	165
O	1423	1428	cases
O	1428	1429	,
O	1430	1436	hazard
O	1437	1442	ratio
O	1443	1444	[
O	1444	1446	HR
O	1446	1447	]
O	1448	1449	0
O	1449	1450	·
O	1450	1452	51
O	1452	1453	,
O	1454	1456	95
O	1456	1457	%
O	1458	1460	CI
O	1461	1462	0
O	1462	1463	·
O	1463	1465	39
O	1465	1466	-
O	1466	1467	0
O	1467	1468	·
O	1468	1470	66
O	1470	1471	,
O	1472	1473	p
O	1473	1474	<
O	1474	1475	0
O	1475	1476	·
O	1476	1480	0001
O	1480	1481	)
O	1481	1482	.

O	1483	1486	The
B-outcome	1487	1496	reduction
O	1497	1500	was
O	1501	1507	larger
O	1508	1510	in
O	1511	1514	the
B-outcome	1515	1520	first
I-outcome	1521	1522	5
I-outcome	1523	1528	years
O	1529	1530	(
B-iv-bin-abs	1530	1532	35
O	1533	1535	vs
B-cv-bin-abs	1536	1538	89
O	1538	1539	,
O	1540	1541	0
O	1541	1542	·
O	1542	1544	39
O	1544	1545	,
O	1546	1547	0
O	1547	1548	·
O	1548	1550	27
O	1550	1551	-
O	1551	1552	0
O	1552	1553	·
O	1553	1555	58
O	1555	1556	,
O	1557	1558	p
O	1558	1559	<
O	1559	1560	0
O	1560	1561	·
O	1561	1565	0001
O	1565	1566	)
O	1566	1567	,
O	1568	1571	but
O	1572	1577	still
O	1578	1589	significant
B-outcome	1590	1595	after
I-outcome	1596	1597	5
I-outcome	1598	1603	years
O	1604	1605	(
B-iv-bin-abs	1605	1607	50
O	1608	1610	vs
B-cv-bin-abs	1611	1613	76
O	1614	1617	new
O	1618	1623	cases
O	1623	1624	,
O	1625	1626	0
O	1626	1627	·
O	1627	1629	64
O	1629	1630	,
O	1631	1632	0
O	1632	1633	·
O	1633	1635	45
O	1635	1636	-
O	1636	1637	0
O	1637	1638	·
O	1638	1640	91
O	1640	1641	,
O	1642	1643	p
O	1643	1644	=
O	1644	1645	0
O	1645	1646	·
O	1646	1649	014
O	1649	1650	)
O	1650	1651	,
O	1652	1655	and
O	1656	1659	not
O	1660	1673	significantly
O	1674	1683	different
O	1684	1688	from
O	1689	1692	the
O	1693	1698	first
O	1699	1700	5
O	1701	1706	years
O	1707	1708	(
O	1708	1709	p
O	1709	1710	=
O	1710	1711	0
O	1711	1712	·
O	1712	1715	087
O	1715	1716	)
O	1716	1717	.

B-outcome	1718	1726	Invasive
I-outcome	1727	1736	oestrogen
I-outcome	1737	1745	receptor
I-outcome	1745	1746	-
I-outcome	1746	1754	positive
I-outcome	1755	1761	breast
I-outcome	1762	1768	cancer
O	1769	1772	was
O	1773	1780	reduced
O	1781	1783	by
O	1784	1786	54
O	1786	1787	%
O	1788	1789	(
O	1789	1791	HR
O	1792	1793	0
O	1793	1794	·
O	1794	1796	46
O	1796	1797	,
O	1798	1800	95
O	1800	1801	%
O	1802	1804	CI
O	1805	1806	0
O	1806	1807	·
O	1807	1809	33
O	1809	1810	-
O	1810	1811	0
O	1811	1812	·
O	1812	1814	65
O	1814	1815	,
O	1816	1817	p
O	1817	1818	<
O	1818	1819	0
O	1819	1820	·
O	1820	1824	0001
O	1824	1825	)
O	1825	1826	,
O	1827	1831	with
O	1832	1833	a
O	1834	1843	continued
O	1844	1855	significant
O	1856	1862	effect
O	1863	1865	in
O	1866	1869	the
O	1870	1876	period
O	1877	1882	after
O	1883	1892	treatment
O	1892	1893	.

O	1894	1895	A
O	1896	1898	59
O	1898	1899	%
B-outcome	1900	1909	reduction
I-outcome	1910	1912	in
I-outcome	1913	1919	ductal
I-outcome	1920	1929	carcinoma
I-outcome	1930	1932	in
I-outcome	1933	1937	situ
O	1938	1941	was
O	1942	1950	observed
O	1951	1952	(
O	1952	1953	0
O	1953	1954	·
O	1954	1956	41
O	1956	1957	,
O	1958	1959	0
O	1959	1960	·
O	1960	1962	22
O	1962	1963	-
O	1963	1964	0
O	1964	1965	·
O	1965	1967	79
O	1967	1968	,
O	1969	1970	p
O	1970	1971	=
O	1971	1972	0
O	1972	1973	·
O	1973	1977	0081
O	1977	1978	)
O	1978	1979	,
O	1980	1990	especially
O	1991	1993	in
O	1994	2006	participants
O	2007	2012	known
O	2013	2015	to
O	2016	2018	be
O	2019	2028	oestrogen
O	2029	2037	receptor
O	2037	2038	-
O	2038	2046	positive
O	2047	2048	(
O	2048	2049	0
O	2049	2050	·
O	2050	2052	22
O	2052	2053	,
O	2054	2055	0
O	2055	2056	·
O	2056	2058	78
O	2058	2059	-
O	2059	2060	0
O	2060	2061	·
O	2061	2063	65
O	2063	2064	,
O	2065	2066	p
O	2066	2067	<
O	2067	2068	0
O	2068	2069	·
O	2069	2073	0001
O	2073	2074	)
O	2074	2075	.

O	2076	2078	No
O	2079	2090	significant
O	2091	2101	difference
O	2102	2104	in
B-outcome	2105	2111	deaths
O	2112	2115	was
O	2116	2124	observed
O	2125	2132	overall
O	2133	2134	(
B-iv-bin-abs	2134	2136	69
O	2137	2139	vs
B-cv-bin-abs	2140	2142	70
O	2142	2143	,
O	2144	2146	HR
O	2147	2148	0
O	2148	2149	·
O	2149	2151	96
O	2151	2152	,
O	2153	2155	95
O	2155	2156	%
O	2157	2159	CI
O	2160	2161	0
O	2161	2162	·
O	2162	2164	69
O	2164	2165	-
O	2165	2166	1
O	2166	2167	·
O	2167	2169	34
O	2169	2170	,
O	2171	2172	p
O	2172	2173	=
O	2173	2174	0
O	2174	2175	·
O	2175	2177	82
O	2177	2178	)
O	2179	2181	or
B-outcome	2182	2185	for
I-outcome	2186	2192	breast
I-outcome	2193	2199	cancer
O	2200	2201	(
B-iv-bin-abs	2201	2204	two
O	2205	2216	anastrozole
O	2217	2219	vs
B-cv-bin-abs	2220	2225	three
O	2226	2233	placebo
O	2233	2234	)
O	2234	2235	.

O	2236	2237	A
O	2238	2249	significant
O	2250	2258	decrease
O	2259	2261	in
B-outcome	2262	2265	non
I-outcome	2265	2266	-
I-outcome	2266	2272	breast
I-outcome	2273	2280	cancers
O	2281	2284	was
O	2285	2293	observed
O	2294	2297	for
O	2298	2309	anastrozole
O	2310	2311	(
B-iv-bin-abs	2311	2314	147
O	2315	2317	vs
B-cv-bin-abs	2318	2321	200
O	2321	2322	,
O	2323	2327	odds
O	2328	2333	ratio
O	2334	2335	0
O	2335	2336	·
O	2336	2338	72
O	2338	2339	,
O	2340	2342	95
O	2342	2343	%
O	2344	2346	CI
O	2347	2348	0
O	2348	2349	·
O	2349	2351	57
O	2351	2352	-
O	2352	2353	0
O	2353	2354	·
O	2354	2356	91
O	2356	2357	,
O	2358	2359	p
O	2359	2360	=
O	2360	2361	0
O	2361	2362	·
O	2362	2366	0042
O	2366	2367	)
O	2367	2368	,
O	2369	2374	owing
O	2375	2384	primarily
O	2385	2387	to
O	2388	2391	non
O	2391	2392	-
O	2392	2400	melanoma
O	2401	2405	skin
O	2406	2412	cancer
O	2412	2413	.

O	2414	2416	No
O	2417	2423	excess
O	2424	2426	of
B-outcome	2427	2436	fractures
O	2437	2439	or
B-outcome	2440	2454	cardiovascular
I-outcome	2455	2462	disease
O	2463	2466	was
O	2467	2475	observed
O	2475	2476	.

O	2477	2481	This
O	2482	2490	analysis
O	2491	2494	has
O	2495	2505	identified
O	2506	2507	a
O	2508	2519	significant
O	2520	2530	continuing
O	2531	2540	reduction
O	2541	2543	in
O	2544	2550	breast
O	2551	2557	cancer
O	2558	2562	with
O	2563	2574	anastrozole
O	2575	2577	in
O	2578	2581	the
O	2582	2586	post
O	2586	2587	-
O	2587	2596	treatment
O	2597	2603	follow
O	2603	2604	-
O	2604	2606	up
O	2607	2613	period
O	2613	2614	,
O	2615	2619	with
O	2620	2622	no
O	2623	2631	evidence
O	2632	2634	of
O	2635	2638	new
O	2639	2643	late
O	2644	2648	side
O	2648	2649	-
O	2649	2656	effects
O	2656	2657	.

O	2658	2665	Further
O	2666	2672	follow
O	2672	2673	-
O	2673	2675	up
O	2676	2678	is
O	2679	2685	needed
O	2686	2688	to
O	2689	2695	assess
O	2696	2699	the
O	2700	2706	effect
O	2707	2709	on
O	2710	2716	breast
O	2717	2723	cancer
O	2724	2733	mortality
O	2733	2734	.

O	2735	2741	Cancer
O	2742	2750	Research
O	2751	2753	UK
O	2753	2754	,
O	2755	2758	the
O	2759	2767	National
O	2768	2774	Health
O	2775	2778	and
O	2779	2786	Medical
O	2787	2795	Research
O	2796	2803	Council
O	2804	2813	Australia
O	2813	2814	,
O	2815	2821	Breast
O	2822	2828	Cancer
O	2829	2837	Research
O	2838	2848	Foundation
O	2848	2849	,
O	2850	2856	Sanofi
O	2857	2864	Aventis
O	2864	2865	,
O	2866	2869	and
O	2870	2881	AstraZeneca
O	2881	2882	.
